Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus

Emerging Microbes and Infections

Volumn 7, Issue 1, 2018, Pages

  Deng, Yao ^a   Lan, Jiaming ^a,b   Bao, Linlin ^c   Huang, Baoying ^a   Ye, Fei ^a   Chen, Yingzhu ^a   Yao, Yanfeng ^c   Wang, Wenling ^a   Qin, Chuan ^c   Tan, Wenjie ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; RECOMBINANT PROTEIN; RECOMBINANT S PROTEIN; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; VIRUS VACCINE; CORONAVIRUS SPIKE GLYCOPROTEIN; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROKARYOTIC CELL; VACCINATION; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS NUCLEOCAPSID; WESTERN BLOTTING; ANIMAL; BLOOD; CORONAVIRUS INFECTION; HUMAN; IMMUNIZATION; IMMUNOLOGY; LUNG; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOGLOBULIN G; LUNG; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINES, INACTIVATED; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 85044961392     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/s41426-018-0056-7     Document Type: Article

References (43)

1. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New Engl. J. Med. 367, 1814-1820 (2012).
2. van Boheemen, S. et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3, https://doi.org/10.1128/mBio.00473-12 (2012).
3. Chan, J. F. et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28, 465-522 (2015).
4. Okba, N. M., Raj, V. S. & Haagmans, B. L. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. Curr. Opin. Virol. 23, 49-58 (2017).
5. Modjarrad, K. et al. A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. Nat. Med. 22, 701-705 (2016).
6. Agnihothram, S. et al. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J. Infect. Dis. 209, 995-1006 (2014).
7. Haagmans, B. L. et al. An orthopoxvirus-based vaccine reduces virus excretion after mers-cov infection in dromedary camels. Science 351, 77-81 (2016).
8. Chi, H. et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine 35, 2069-2075 (2017).
9. Muthumani, K. et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci. Transl. Med. 7, 301ra132 (2015).
10. Coleman, C. M. et al. MERS-CoV spike nanoparticles protect mice from MERSCoV infection. Vaccine 35, 1586-1589 (2017).
11. Wang, L. et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 6, 7712 (2015).
12. Lu, G. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500, 227-231 (2013).
13. Liu, W. J. et al. Protective T cell responses featured by concordant recognition of middle east respiratory syndrome coronavirus-derived CD8+ T cell epitopes and host MHC. J. Immunol. 198, 873-882, https://doi.org/10.4049/jimmunol.1601542 (2017).
14. Tai, W. et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 499, 375-382 (2016).
15. Lan, J. et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS ONE 9, e112602 (2014).
16. Jiaming, L. et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine 35, 10-18 (2017).
17. Lan, J. et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against middle east respiratory syndrome coronavirus challenge. EBioMedicine 2, 1438-1446 (2015).
18. Gü, X. et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 145, 476-484 (2015).
19. Zhang, N. et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell. Mol. Immunol. 13, 180-190 (2015).
20. Agrawal A. S., et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Human vaccines & immunotherapeutics, 1-6, https://doi.org/10.1080/21645515.2016.1177688 (2016).
21. Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201-12215 (2011).
22. Honda-Okubo, Y. et al. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J. Virol. 89, 2995-3007 (2015).
23. Iwata-Yoshikawa, N. et al. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALBc mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J. Virol. 88, 8597-8614 (2014).
24. Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).
25. Deming, D. et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3, e525 (2006).
26. Yasui, F. et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181, 6337-6348 (2008).
27. Shirota, H. & Klinman, D. M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev. Vaccin. 13, 299-312 (2014).
28. Kapikian, A. Z.,Mitchell, R. H., Chanock, R. M., Shvedoff, R. A. & Stewart, C. E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405 (1969).
29. Chuai, X. et al. Poly(I:C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting. PLoS ONE 8, e54126 (2013).
30. Chen, H. et al. Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice. Chin. J. Biotechnol. 26, 74 (2010).
31. Chen, Y. et al. A novel neutralizing monoclonal antibody targeting the Nterminal domain of the MERS-CoV spike protein. Emerg. Microbes Infect. 6, e37 (2017).
32. Wang, Y. et al. Prokaryotic expression, purification and identification of the N protein of middle east respiratory syndrome coronavirus. Chinese Journal of Microbiology and Immunology 10, 764-769. (2014).
33. Song, F. et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virusneutralizing antibodies. J. Virol. 87, 11950-11954 (2013).
34. Du, L. et al. MERS-CoV spike protein: a key target for antivirals. Expert Opin. Ther. Targets 21, 131-143 (2017).
35. Peng, H. et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 351, 466-475 (2006).
36. Pang, H. et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J. Gen. Virol. 85, 3109-3113 (2004).
37. Buchholz, U. J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci. USA 101, 9804-9809 (2004).
38. Armstrong, J., Niemann, H., Smeekens, S., Rottier, P. & Warren, G. Sequence and topology of a model intracellular membrane protein, E1 glycoprotein, from a coronavirus. Nature 308, 751-752 (1984).
39. Pervushin, K. et al. Structure and inhibition of the SARS coronavirus envelope protein ion channel. PLoS Pathog. 5, e1000511 (2009).
40. Liu, J. et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J. Infect. Dis. 202, 1171-1180 (2010).
41. Liu, W. J. et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antivir. Res. 137, 82-92 (2017).
42. Yang, Y. et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4, 951-961 (2013).
43. Zhao, J. et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl Acad. Sci. USA 111, 4970-4975 (2014).